Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.93
-1.6%
$0.97
$0.73
$11.90
$20.15M0.52113,276 shs4,923 shs
IsoPlexis Co. stock logo
ISO
IsoPlexis
$0.76
$0.86
$0.60
$5.10
$30.28M1.3268,375 shsN/A
Precipio, Inc. stock logo
PRPO
Precipio
$6.03
-2.4%
$6.37
$4.75
$14.80
$8.62M1.616,322 shs9,309 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
+0.49%+21.51%-2.57%-26.91%-89.60%
IsoPlexis Co. stock logo
ISO
IsoPlexis
0.00%0.00%0.00%0.00%0.00%
Precipio, Inc. stock logo
PRPO
Precipio
+5.38%-7.90%+1.50%-0.08%-46.86%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
2.6858 of 5 stars
1.32.00.04.72.42.50.6
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
0.532 of 5 stars
2.04.00.00.00.00.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
2.50
Moderate Buy$1.007.52% Upside
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/A$40.00563.35% Upside

Current Analyst Ratings

Latest ISO, PRPO, and AXDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2024
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/1/2024
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$2.00 ➝ $1.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$12.06M1.67N/AN/A($1.37) per share-0.68
IsoPlexis Co. stock logo
ISO
IsoPlexis
$16.76M1.81N/AN/A$1.04 per share0.73
Precipio, Inc. stock logo
PRPO
Precipio
$15.20M0.57N/AN/A$10.16 per share0.59

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$4.89N/AN/AN/A-454.95%N/A-170.54%5/9/2024 (Estimated)
IsoPlexis Co. stock logo
ISO
IsoPlexis
-$106M-$2.70N/AN/AN/A-632.41%-127.86%-71.41%N/A
Precipio, Inc. stock logo
PRPO
Precipio
-$5.85M-$4.56N/AN/A-38.51%-51.75%-37.93%5/10/2024 (Estimated)

Latest ISO, PRPO, and AXDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/29/2024Q4 2023
Precipio, Inc. stock logo
PRPO
Precipio
N/A-$0.41-$0.41-$1.70N/A$4.33 million
3/28/2024Q4 2023
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$0.62-$0.89-$0.27-$0.89$3.80 million$3.03 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
2.03
1.76
IsoPlexis Co. stock logo
ISO
IsoPlexis
1.12
4.06
2.50
Precipio, Inc. stock logo
PRPO
Precipio
0.01
1.17
1.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17.14%
IsoPlexis Co. stock logo
ISO
IsoPlexis
44.91%
Precipio, Inc. stock logo
PRPO
Precipio
10.45%

Insider Ownership

CompanyInsider Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
43.60%
IsoPlexis Co. stock logo
ISO
IsoPlexis
6.40%
Precipio, Inc. stock logo
PRPO
Precipio
10.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17921.66 million12.22 millionOptionable
IsoPlexis Co. stock logo
ISO
IsoPlexis
45939.76 million37.22 millionNot Optionable
Precipio, Inc. stock logo
PRPO
Precipio
511.43 million1.28 millionNo Data

ISO, PRPO, and AXDX Headlines

SourceHeadline
Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.64Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.64
americanbankingnews.com - April 24 at 3:46 AM
Precipio, Inc. (PRPO) Latest Stock News & Headlines - Yahoo FinancePrecipio, Inc. (PRPO) Latest Stock News & Headlines - Yahoo Finance
finance.yahoo.com - April 20 at 10:44 PM
Precipio Inc PRPOPrecipio Inc PRPO
morningstar.com - April 19 at 4:06 PM
Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.62Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.62
americanbankingnews.com - April 16 at 3:36 AM
Precipio Announces Year end 2023 Shareholder Update CallPrecipio Announces Year end 2023 Shareholder Update Call
globenewswire.com - March 25 at 5:00 PM
Precipio, Inc. (PRPO)Precipio, Inc. (PRPO)
ca.finance.yahoo.com - March 12 at 9:50 AM
Precipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, PredictionsPrecipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 5:33 AM
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYPrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
finance.yahoo.com - February 13 at 5:30 PM
Precipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for CancerPrecipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for Cancer
finanznachrichten.de - February 6 at 4:00 PM
Precipio’s Q4 cash burn from operations drops below $100K for full quarterPrecipio’s Q4 cash burn from operations drops below $100K for full quarter
msn.com - January 23 at 4:19 PM
Precipio, Inc.: Precipios Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterPrecipio, Inc.: Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
finanznachrichten.de - January 23 at 4:19 PM
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterPrecipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
finance.yahoo.com - January 23 at 4:19 PM
Precipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in JapanPrecipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in Japan
finanznachrichten.de - January 17 at 3:59 PM
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in JapanPrecipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
finance.yahoo.com - January 17 at 3:59 PM
Precipio Announces Christina Valauri joins the Board of DirectorsPrecipio Announces Christina Valauri joins the Board of Directors
finance.yahoo.com - January 2 at 9:25 AM
Precipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024Precipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
finanznachrichten.de - December 15 at 8:20 AM
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
finance.yahoo.com - December 14 at 7:47 PM
Precipio: Regulation Fd Disclosure, Financial Statements And ExhibitsPrecipio: Regulation Fd Disclosure, Financial Statements And Exhibits
cbonds.com - November 18 at 7:00 AM
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
finance.yahoo.com - October 18 at 9:36 AM
Precipio, Inc.: Precipios Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023Precipio, Inc.: Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
finanznachrichten.de - October 3 at 1:42 PM
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
finance.yahoo.com - October 3 at 1:42 PM
Precipio Continues to Sign New HemeScreen™ CustomersPrecipio Continues to Sign New HemeScreen™ Customers
finance.yahoo.com - September 28 at 2:36 PM
Precipio Reduces Product Revenue Result Needed for Cash Flow BreakevenPrecipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
finance.yahoo.com - September 25 at 3:15 PM
Precipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq CompliancePrecipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq Compliance
finanznachrichten.de - September 22 at 10:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Accelerate Diagnostics logo

Accelerate Diagnostics

NASDAQ:AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
IsoPlexis logo

IsoPlexis

NASDAQ:ISO
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Precipio logo

Precipio

NASDAQ:PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.